Discover open access scientific publications

Search, annotate, share and cite publications

Publications by P.L. Zinzani

Pembrolizumab Monotherapy in Patients With Primary Refractory Classical Hodgkin Lymphoma: Subgroup Analysis of the Phase 2 Keynote-087 Study

Hematological Oncology

English

Primary Analysis Results of the Single-Arm Phase Ii Study of Mor208 Plus Lenalidomide in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (L-Mind)

Hematological Oncology

English

Copanlisib Treatment of Patients With Relapsed or Refractory Marginal Zone Lymphoma

Hematological Oncology

English

Phase 1b Keynote-013 Study of Pembrolizumab in Patients With Classic Hodgkin Lymphoma After Brentuximab Vedotin Failure: Results of >4 Years of Follow-Up

Hematological Oncology

English

Nivolumab for Relapsed/Refractory Classical Hodgkin Lymphoma After Autologous Transplant: Full Results After Extended Follow-Up of the Phase 2 Checkmate 205 Trial

Hematological Oncology

English

Phase Ib Study of Cc-122 in Combination With Obinutuzumab (Ga101): Relapsed or Refractory (R/R) Patients With B-Cell Non-Hodgkin Lymphomas (Nhl)

Hematological Oncology

English

Pet/Ct-Guided Biopsy for the Diagnosis of Lymphoma

Hematological Oncology

English

Efficacy of Mogamulizumab in Previously Treated Patients With Less Advanced Mycosis Fungoides: Results From the Mavoric Study

Hematological Oncology

English

Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase 2 Checkmate 436 Study

Hematological Oncology

English

Final Data From the Phase 3 Alcanza Study: Brentuximab Vedotin (Bv) vs Physician's Choice (Pc) in Patients (Pts) With Cd30-Positive (Cd30+) Cutaneous T-Cell Lymphoma (Ctcl)

Hematological Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by P.L. Zinzani

Pembrolizumab Monotherapy in Patients With Primary Refractory Classical Hodgkin Lymphoma: Subgroup Analysis of the Phase 2 Keynote-087 Study

Primary Analysis Results of the Single-Arm Phase Ii Study of Mor208 Plus Lenalidomide in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (L-Mind)

Copanlisib Treatment of Patients With Relapsed or Refractory Marginal Zone Lymphoma

Phase 1b Keynote-013 Study of Pembrolizumab in Patients With Classic Hodgkin Lymphoma After Brentuximab Vedotin Failure: Results of >4 Years of Follow-Up

Nivolumab for Relapsed/Refractory Classical Hodgkin Lymphoma After Autologous Transplant: Full Results After Extended Follow-Up of the Phase 2 Checkmate 205 Trial

Phase Ib Study of Cc-122 in Combination With Obinutuzumab (Ga101): Relapsed or Refractory (R/R) Patients With B-Cell Non-Hodgkin Lymphomas (Nhl)

Pet/Ct-Guided Biopsy for the Diagnosis of Lymphoma

Efficacy of Mogamulizumab in Previously Treated Patients With Less Advanced Mycosis Fungoides: Results From the Mavoric Study

Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase 2 Checkmate 436 Study

Final Data From the Phase 3 Alcanza Study: Brentuximab Vedotin (Bv) vs Physician's Choice (Pc) in Patients (Pts) With Cd30-Positive (Cd30+) Cutaneous T-Cell Lymphoma (Ctcl)